Inventor
AXT SABINE
US21 patents
⚠️ This page may combine multiple inventors who share the name “AXT SABINE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
THERAVANCE INC
7 patentsUS7700777B2Apr 20, 2010
Crystalline forms of a biphenyl compound
THERAVANCE INC42 citations96
US8377965B2Feb 19, 2013
Crystalline forms of a biphenyl compound
THERAVANCE INC20 citations92
US7015346B2Mar 21, 2006
Short-acting sedative hypnotic agents for anesthesia and sedation
THERAVANCE INC14 citations92
US7060712B2Jun 13, 2006
Crystalline form of aryl aniline β2 adrenergic receptor agonist
THERAVANCE INC16 citations83
US7514425B2Apr 7, 2009
Short-acting sedative hypnotic agents for anesthesia and sedation
THERAVANCE INC6 citations73
US6887866B2May 3, 2005
Short-acting sedative hypnotic agents for anesthesia and sedation
THERAVANCE INC10 citations73
US7939689B2May 10, 2011
Short-acting sedative hypnotic agents for anesthesia and sedation
THERAVANCE INC0 citations51
AXT SABINE
4 patentsUS8242137B2Aug 14, 2012
Crystalline forms of a biphenyl compound
AXT SABINE24 citations95
US9249099B2Feb 2, 2016
Crystalline forms of a biphenyl compound
AXT SABINE8 citations92
US8921395B2Dec 30, 2014
Crystalline forms of a biphenyl compound
AXT SABINE8 citations92
US8716313B2May 6, 2014
Crystalline forms of a biphenyl compound
AXT SABINE14 citations92
THERAVANCE BIOPHARMA R&D IP LLC
3 patentsUS9656993B2May 23, 2017
Crystalline forms of a biphenyl compound
THERAVANCE BIOPHARMA R&D IP LLC10 citations92
US11390603B2Jul 19, 2022
Crystalline forms of a biphenyl compound
THERAVANCE BIOPHARMA R&D IP LLC5 citations84
US10577347B2Mar 3, 2020
Crystalline forms of a biphenyl compound
THERAVANCE BIOPHARMA R&D IP LLC6 citations84
LEADBETTER MICHAEL R
3 patentsUS8101791B2Jan 24, 2012
Aminotetralin compounds as mu opioid receptor antagonists
LEADBETTER MICHAEL R5 citations73
US8314128B2Nov 20, 2012
Aminotetralin compounds as mu opioid receptor antagonists
LEADBETTER MICHAEL R4 citations62
US8497287B2Jul 30, 2013
Aminotetralin compounds as mu opioid receptor antagonists
LEADBETTER MICHAEL R1 citations51